Satellos Bioscience Inc. (TSE:MSCL) has released an update.
Satellos Bioscience Inc. has released its Q1 2024 financial results, revealing a strong cash position of $33.2 million and significant progress in its clinical development program. The company is gearing up to start Phase 1 trials for SAT-3247, its promising oral drug candidate aimed at treating Duchenne muscular dystrophy and other muscle conditions. Satellos has successfully conducted preclinical studies, GMP manufacturing, and presented positive data at a recent scientific conference, positioning itself for regulatory submission and a first-in-human study in mid-2024.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
